Cargando…

Correlation between Levels of Serum Lipoprotein-Associated Phospholipase A2 and Soluble Suppression of Tumorigenicity 2 and Condition of Acute Heart Failure Patients and Their Predictive Value for Prognosis

OBJECTIVE: To explore the correlation between levels of serum lipoprotein-associated phospholipase A2 (LP-PLA2) and soluble suppression of tumorigenicity 2 (sST2) and condition of acute heart failure (AHF) patients and their predictive value for prognosis. METHODS: The data of patients who complaine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jinjin, Wang, Lei, Zhao, Zhikun, Li, Liang, Xia, Yunfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702322/ https://www.ncbi.nlm.nih.gov/pubmed/34956555 http://dx.doi.org/10.1155/2021/1525190

Ejemplares similares

Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
por: Huang, Dong-Hui, et al.
Publicado: (2016)

Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure
por: Öncel, Can Ramazan
Publicado: (2018)

Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis
por: Yang, Hyun Suk, et al.
Publicado: (2016)

Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis
por: Shi, Yujiao, et al.
Publicado: (2022)

Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure
por: Gül, İbrahim, et al.
Publicado: (2017)

Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction
por: Cui, Yameng, et al.
Publicado: (2018)

Prognostic Value of β1 Adrenergic Receptor Autoantibody and Soluble Suppression of Tumorigenicity-2 in Patients With Acutely Decompensated Heart Failure
por: Sun, Yanxiang, et al.
Publicado: (2022)

Soluble Suppression of Tumorigenicity-2 Associates With Ventilator Dependence in Coronavirus Disease 2019 Respiratory Failure
por: Alladina, Jehan W., et al.
Publicado: (2021)

Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis
por: Guo, Guangying, et al.
Publicado: (2021)

Serum soluble suppression of tumorigenicity 2 as a novel inflammatory marker predicts the severity of acute pancreatitis
por: Zhang, Yan, et al.
Publicado: (2021)

Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
por: Iannazzo, Francesco, et al.
Publicado: (2022)

Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity
por: Kang, Dong Woo, et al.
Publicado: (2020)

The diagnostic value of lipoprotein-associated phospholipase A2 in early diabetic nephropathy
por: Zhai, Yan, et al.
Publicado: (2023)

Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity‐2
por: Gerber, Yariv, et al.
Publicado: (2017)

Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect
por: Pratama, Reza S., et al.
Publicado: (2020)

Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction
Publicado: (2017)

Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: AbouEzzeddine, Omar F., et al.
Publicado: (2017)

Evaluation of lipoprotein-associated Phospholipase A2 in Healthy Chinese Han Adult Serum
por: Feng, Li-Min, et al.
Publicado: (2014)

The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis
por: Liu, Niannian, et al.
Publicado: (2020)

Lipoprotein‐associated phospholipase A2: The story continues
por: Huang, Fubao, et al.
Publicado: (2019)

Relationship of Placental and Serum Lipoprotein-Associated Phospholipase A2 Levels with Hypertensive Disorders of Pregnancy
por: Wang, Jing, et al.
Publicado: (2022)

Soluble suppression of tumorigenicity 2 as outcome predictor after cardiopulmonary resuscitation: an observational prospective study
por: Rezar, Richard, et al.
Publicado: (2021)

Soluble suppression of tumorigenicity 2 associated with fulminant myocarditis in children: A retrospective observational study
por: Hou, Wenquan, et al.
Publicado: (2023)

Soluble suppression of tumorigenicity 2 is a potential predictor of post-liver transplant renal outcomes
por: Moon, Jong Joo, et al.
Publicado: (2023)

Soluble Suppression of Tumorigenicity-2 as a Candidate Prognostic Marker for Stroke: A Systematic Review
por: Ahmadzadeh, Koohyar, et al.
Publicado: (2023)

A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension
por: Luk, King Sum, et al.
Publicado: (2017)

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease
por: Doody, Rachelle S., et al.
Publicado: (2015)

Diagnostic Predictive Value of Tryptase, Serum Amyloid A and Lipoprotein-Associated Phospholipase A2 Biomarker Groups for Large Atherosclerotic Cerebral Infarction
por: Jia, Wenhui, et al.
Publicado: (2022)

Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis
por: Gu, Linlin, et al.
Publicado: (2019)

Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation
por: Tan, Ruopeng, et al.
Publicado: (2021)

Soluble suppression of tumorigenicity 2 associated with atrial fibrillation detected after stroke: A retrospective study
por: Hou, Wenquan, et al.
Publicado: (2023)

Interleukin-33/ Suppression of Tumorigenicity 2 in Renal Fibrosis: Emerging Roles in Prognosis and Treatment
por: Tan, Xiao-Yang, et al.
Publicado: (2022)

Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups
por: Nah, Eun‐Hee, et al.
Publicado: (2020)

Racial variation in lipoprotein-associated phospholipase A(2 )in older adults
por: Lee, Keane K, et al.
Publicado: (2011)

Secreted phospholipase A(2), lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics
por: Yamamoto, Kei, et al.
Publicado: (2011)

Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis
por: Wang, Yuan, et al.
Publicado: (2022)

Prognostic Utility of Soluble Suppression of Tumorigenicity 2 level as a Predictor of Clinical Outcomes in Incident Hemodialysis Patients
por: Seo, Suk Min, et al.
Publicado: (2018)

Soluble Suppression of Tumorigenicity 2 is Directly Correlated with Glycated Hemoglobin in Individuals with an Average glycemia in the Normal/Prediabetes Range
por: Hasan, Amal, et al.
Publicado: (2020)

Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
por: Arnaldos-Carrillo, María, et al.
Publicado: (2023)

Mouse Plasminogen Has Oxidized Phosphatidylcholine Adducts That Are Not Metabolized by Lipoprotein-Associated Phospholipase A(2) under Basal Conditions
por: Edelstein, Celina, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_frbdnnt119orb39di5a5jnq8g7